Stem Cell Pioneer, Celltex Therapeutics, Announces Sponsorship of Regenera Global Conference
HOUSTON (PRWEB) JUNE 17, 2016
Houston-based biotechnology company and adult stem cell pioneer, Celltex Therapeutics Corporation, is proud to announce its sponsorship of the upcoming Regenera Global “Regenerative Medicine 2:0: Redefining the Practice” conference, to be held at the Grand Lucayan Resort in Freeport, Grand Bahama, June 23-25, 2016. Celltex will present the “2016 Celltex Outstanding Investigator Award in Regenerative Medicine” on Saturday, June 25, to a deserving researcher whose novel and significant work has had, or may have, a far-reaching impact on the clinical translation of Regenerative Medicine for health or anti-aging applications.
Celltex Chief Medical Officer, Dr. Stanley Jones, will deliver a presentation titled, “The Good Fight: The Celltex Journey to Make MSC Therapy Mainstream” providing attendees with an inside look at one of the only commercial adult stem cell companies in the United States operating a best-in-class FDA-regulated stem cell laboratory and bank in Houston, Texas.
“Celltex was one of the first adult stem cell companies to enter the commercial space in the United States, and with that, experienced and survived many challenges that come with entering unchartered territory,” says Celltex CEO, David Eller. “This is a pivotal time for the future of regenerative medicine, and we look forward to sharing our insights and lessons learned with peers who share our commitment to making adult stem cell therapy accessible in America.”
Celltex Therapeutics is a leader in autologous stem cell therapy, utilizing proprietary technology to isolate, grow and cryopreserve (bank) hundreds of millions of individuals’ own adult mesenchymal stem cells (MSCs) for therapeutic use. The therapy, administered by licensed physicians at Hospital Galenia in Cancun, has been used to improve quality of life for those suffering from injuries, as well as autoimmune, vascular and other degenerative diseases.
Many Celltex clients have become a testament to the promise of adult stem cell therapy in their local communities, showing improvements after therapy when conventional treatment failed to relieve chronic pain or loss of independence from degenerative conditions.
“We are proud to welcome Celltex to the Regenera Global conference,” says Luis Martinez, MD, CEO of Regenera Global, Inc. “Their experience in the field of stem cell therapy brings with it invaluable perspective and lessons as we seek to identify best practices for stem cell manufacturing and therapy today and in the future.”
For more information about Celltex and the process of stem cell banking or to review frequently asked questions about stem cell therapy, please visithttp://www.celltexbank.com.
ABOUT CELLTEX THERAPEUTICS CORPORATION:
Celltex is a Houston-based biotechnology company that is leading the United States into the future of regenerative medicine with its proprietary technology that that isolates, multiplies and stores autologous, adult, adipose (fat tissue)-derived mesenchymal stem cells (MSCs) to be used for regenerative therapy in a number of conditions including vascular, autoimmune and degenerative diseases. Celltex is committed to expanding the use of adult stem cell therapy for all and is currently working with leading American academic institutions on several clinical trials that will help secure the future of regenerative medicine here in the United States. For more information about Celltex Therapeutics Corporation, please visit http://www.celltexbank.com.
ABOUT REGENERA GLOBAL, INC.:
Based in Puerto Rico, Regenera Global, Inc. is a bio-technology firm focused on developing and commercializing innovative therapies, providing consulting services and educational events to physicians and healthcare practitioners to expand their knowledge of regenerative medicine clinical applications which may include, but is not limited to, stem cell and gene therapy, tissue engineering, and select medical devices. Regenera Global is working to bridge the gap of access to regenerative medicine between the progress made through research and what is available clinically to physicians and patients.
